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KEYWORDS	
	 Several	 new	 substituted	 sulfonamides	 and	 sulfinyl	 compound	derivatives	were	 obtained	 by
the	reaction	of	2‐thioxo‐1,2,4‐triazolo[1,5‐a]pyridine	and	pyrimidine	thiol	derivatives	with	(2‐
chloromethyl)benzimidazole	 and/or	 (2‐chloromethyl)benzooxazole.	 Structures	 of	 the	 newly
synthesized	 products	 have	 been	 deduced	 on	 the	 basis	 of	 spectral	 and	 analytical	 data.	 The
synthesized	compounds	were	screened	for	their	antimicrobial	activity.	
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1.	Introduction	
	
Heterocycles	 containing	 sulfonamide	 moieties	 have	
attracted	 obvious	 attention	 due	 to	 their	 significant	 biological	
properties	and	their	role	as	pharmacohores	[1‐6].	Studies	have	
shown	that	sulfonamide	compounds	were	used	as	antibacterial	
[7‐9],	 antifungal	 [9,10],	 antiviral	 [11],	 anticancer	 [12],	 ant‐
inflammatory,	analgesic	[13‐15],	and	antibacterial	agents	[16].	
Also,	 a	 wide	 variety	 of	 benzimidazole	 derivatives	 have	 been	
described	 for	 their	 chemotherapeutic	 importance	 [17‐23]	 and	
oxazole	 derivatives	 play	 very	 important	 role	 in	 the	 manufac‐
turing	 process	 of	 various	 biologically	 active	 drugs	 as	
anticancer,	antimicrobial,	antidiabetic	and	antiobesity	[24,25].	
A	 large	 number	 of	 heterocyclic	 compounds	 containing	
pyridine	 rings	 are	 associated	 with	 diverse	 pharmacological	
properties	 such	 as	 anticancer,	 antimicrobial,	 anticonvulsant,	
antifungal,	antiviral,	anti‐HIV,	and	anti‐microbacterial	activities	
[26,27].	 The	 pyridine	 ring	 is	 one	 of	 the	 most	 well‐known	
systems	 among	 the	 naturally	 occurring	 heterocycles,	 pyridine	
and	 fused	 pyridine	 moieties	 present	 in	 numerous	 natural	
products	 such	 as	 quinoline	 and	 isoquinoline	 alkaloids	 and	
nicotine	and	its	analogs	[28].	
In	 the	 recent	 years,	 the	 biological	 properties	 of	 1,2,4‐
triazoles	have	been	widely	investigated.	They	were	shown	to	be	
effective	 as	 anti‐inflammatory,	 antibacterial,	 anticonvulsant,	
dephlogisticate,	 anti‐depressant,	 antifungal,	 anticancer,	
antibacterial	properties,	antipyretic,	and	antifungal	agents	[29‐
32].	 Pyridyl	 methyl	 sulfinyl	 benzimdizole	 derivatives	 such	 as	
omeprazole,	 rebeprazole,	 lansoprazole,	 pantoprazole,	 esomp‐
tazol	are	the	drug	of	choice	for	the	acid	related	gastrointestinal	
disorders.	These	drugs	act	by	inhibiting	the	proton	pump	(H/K	
ATPase)	which	 involved	 in	 the	 acid	 secretion	 in	 the	 stomach	
[33].	
Moreover,	pyrimidine	moiety	have	been	widely	used	in	the	
design	 of	 biologically	 active	 agents,	 structure	 containing	 such	
units	often	play	an	essential	role	owing	to	their	wide	range	of	
biological	 activity	 particularly	 in	 cancer	 and	 virus	 research	
[34,35].	
Coumarins	 are	 a	 structural	 scaffold	 in	 the	 numerous	
natural	products	and	one	of	the	well‐known	oxygen	containing	
heterocycles	 showing	 a	 variety	 of	 biological	 applications	 [36‐
38].	As	a	part	of	our	ongoing	studies	we	now	describe	synthesis	
of	 new	1,2,4‐triazolo[1,5‐a]pyridine,	 pyrimidine	 sulfonamides,	
sulfinyl	derivatives	and	in	connection	with	our	previous	studies	
[39‐47],	 on	 poly‐functionally	 heteroaromatic	 compounds,	 we	
reported	 here	 1,2,4‐triazolo[1,5‐a]pyridine,	 pyrimidine,	 and	
coumarin	with	benzimidazole,	 and/or	benzooxazole	moiety	 in	
single	molecular	framework	with	evaluation	of	their	biological	
activities	 that	 we	 are	 expected	 to	 have	 enhanced	 biological	
activities	which	is	the	goal	of	our	study.	
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Scheme	1
	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
Melting	 points	 were	 determined	 on	 a	 Gallen‐kamp	
apparatus	and	are	uncorrected.	The	 IR	spectra	were	recorded	
on	 Shimadzu	 FT‐IR	 8101	PC	 infrared	 spectrophotometer.	 The	
1H	NMR	spectra	were	determined	in	DMSO‐d6	at	300	MHz	on	a	
Varian	 Mercury	 VX	 300	 NMR	 spectrometer	 using	 TMS	 as	 an	
internal	 standard.	 Mass	 spectra	 were	measured	 on	 a	 GC/MS‐
QP1000	 EX	 spectrometer	 at	 70	 Ev.	 Elemental	 analyses	 were	
carried	 out	 at	 the	 Microanalytical	 Center	 of	 Cairo	 University.	
Ethyl	 6‐cyano‐7‐(4‐methoxyphenyl)‐5‐oxo‐2‐thioxo‐1,2,3,5‐
tetrahydro[1,2,4]triazolo[1,5‐a]pyridine‐8‐carboxylate	[48]	(1)	
and	 2‐(chloromethyl)benzimidazole	 or	 2‐(chloromethyl)	
benzooxazole	 (2a,b)	were	prepared	according	 to	 the	reported	
literature	[49‐51]	(Scheme	1).	
	
2.2.	Synthesis	
	
2.2.1.	General	procedure	for	synthesis	of	compounds	3a,	3b,	
9	and	13	
	
Sodium	(25	mmol)	was	added	to	a	solution	of	compound	1,	
8	 and	 12	 (20	 mmol)	 in	 anhydrous	 MeOH	 (100	 mL)	 and	 the	
mixture	 was	 stirred	 vigorously	 for	 1	 h,	 2‐(chloromethyl)	
benzimidazole	 and/or	 2‐(chloromethyl)benzooxazole	 (2a,b)	
(20	mmol)	was	added	portion‐wise	 to	 the	mixture	 and	 left	 to	
stirring	for	3	days.	The	reactions	mixture	was	triturated	was	ice	
water	 containing	 HCl.	 A	 yellow	 to	 brown	 precipitate	 was	
formed,	filtered	off	and	washed	was	water	several	times,	dried	
and	recrystallized	from	the	appropriate	solvent	(Scheme	1‐3).	
Ethyl	2‐((1H‐benzo[d]imidazol‐2‐yl)methylthio)‐6‐cyano‐3,5‐
dihydro‐7‐(4‐methoxyphenyl)‐5‐oxo‐[1,2,4]‐triazolo[1,5‐a]	 pyri	
dine‐8‐carboxylate	 (3a):	Recrystallized	 from	DMF/	H2O.	Color:	
Brown.	Yield:	69%.	M.p.:	195‐196	C.	FT‐IR	(KBr,	,	cm‐1):	3375,	
3268	 (2NH),	 3115	 (CH),	 2905,	 2850	 (CH)	 2212	 (CN),	 1685	
(C=O),	1664	(C=O),	1628	(C=N),	1586	(C=C).	1H	NMR	(300	MHz,	
DMSO‐d6,	δ,	ppm):	1.17	(t,	3H,	CH3),	3.76	(s,	3H,	OCH3),	4.03	(q,	
2H,	CH2),	4.64	(s,	2H,	SCH2),	8.64	(s,	1H,	NH,	D2O‐exchangeable),	
6.62	(d,	2H,	Ar‐H),	7.31	(d,	2H,	Bz‐H),	7.75	(d,	2H,	Bz‐H),	7.80	(d,	
2H,	 Ar‐H),	 11.43	 (s,	 1H,	 NH,	D2O‐exchangeable).	 13C	 NMR	 (75	
MHz,	CDCl3,	δ,	ppm):	168.8	(C‐7),	167,	164.5	(2C=O),	158.9	(C‐
ArOCH3‐p),	152.1,	147.2	(C‐triazole),	142.6	(C‐imidazole),	116.4	
(CN),	115.7	(C‐6),	109.4	(C‐8),	114.5,	115.2,	123.3,	124.7,	127.9	
(C‐Ar),	62.1	(CH2),	55.8	(OCH3),	33.4	(CH2S),	13.8	(CH3).	MS	(EI,	
m/z	 (%)):	500	(M+,	52).	Anal.	 calcd.	 for	C25H20N6O4S:	C,	59.99;	
H,	4.03;	N,	16.79.	Found:	C,	59.95;	H,	3.99;	N,	16.73%.	
Ethyl	 2‐((benzo[d]oxazol‐2‐yl)methylthio)‐6‐cyano‐3,5‐
dihydro‐7‐(4‐methoxyphenyl)‐5‐oxo‐[1,2,4]‐triazolo[1,5‐a]pyridi	
ne‐8‐carboxylate	 (3b):	 Recrystallized	 from	 DMF/	 H2O.	 Color:	
Pale	brown.	Yield:	56%.	M.p.:	182	C.	FT‐IR	(KBr,	,	cm‐1):	3263	
(NH),	 3119	 (CH),	 2910,	 2846	 (CH)	 2204	 (CN),	 1689	 (C=O),	
1668	 (C=O),	 1632	 (C=N);	 1579	 (C=C).	 1H	 NMR	 (300	 MHz,	
DMSO‐d6,	δ,	ppm):	1.14	(t,	3H,	CH3),	3.78	(s,	3H,	OCH3),	4.09	(q,	
2H,	CH2),	4.61	(s,	2H,	SCH2),	8.89	(s,	1H,	NH,	D2O‐exchangeable),	
6.64‐7.84	(m,	8H,	Ar‐H).	MS	(EI,	m/z	(%)):	501	(M+,	62).	Anal.	
calcd.	 for	 C25H19N5O5S:	 C,	 59.87;	 H,	 3.82;	 N,	 13.96.	 Found:	 C,	
59.91;	H,	3.81;	N,	13.94%.		
3‐(2‐((1H‐Benzo[d]imidazol‐2‐yl)methylthio)‐6‐ethoxypyrimi	
din‐4‐yl)‐2H‐chromen‐2‐one	 (9):	 Recrystallized	 from	 dioxane.	
Color:	Pale	yellow.	Yield:	73%.	M.p.:	175	C.	FT‐IR	(KBr,	,	cm‐
1):3279	 (NH),	3119	 (CH),	 2896,	 2847	 (CH),	1691	 (C=O),	 1627	
(C=N);	1582	(C=C).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	1.27	
(t,	3H,	CH3),	3.82	(q,	2H,	CH2),	4.39	(s,	2H,	SCH2),	6.79	(s,	1H,	H‐
5),	7.03‐7.11	(m,	8H,	Ar‐H),	8.05	(s,	1H,	H‐4chromen),	11.13	(s,	1H,	
NH,	 D2O‐exchangeable).	 13C	 NMR	 (75	 MHz,	 CDCl3,	 δ,	 ppm):	
169.4	 (C‐4pyrimidine),	 169.2	 (C‐2pyrimidine),	 165	 (C=O),	 162.7	 (C‐
6pyrimidine),	 151.8	 (C‐8a	 chromen),	 146.5	 (C‐4chromen),	 143.5	 (C‐
2imidazole),	 139.6	 (C‐3a,	 8aimidazole),	 107.3	 (C‐5pyrimidine),	 128.9,	
127.6,	125.7,	123.2,	121.3,	122.1,	115.5	(C‐Ar),	64.1	(CH2),	34.9	
(CH2S),	14.7	(CH3).	MS	(EI,	m/z	(%)):	430	(M+,	86).	Anal.	calcd.	
for	C23H18N4O3S:	C,	64.17;	H,	4.21;	N,	13.01.	Found:	C,	64.04;	H,	
4.16;	N,	13.05%.	
Ethyl	 2‐(((8‐(ethoxycarbonyl)‐6‐cyano‐3,5‐dihydro‐7‐(4‐
methoxyphenyl)‐5‐oxo‐[1,2,4]triazolo[1,5‐a]pyridine‐2‐ylthio)	
methyl)‐sulfanyl)‐6‐cyano‐3,5‐dihydro‐7‐(4‐methoxyphenyl)‐
5‐oxo‐[1,2,4]‐triazolo[1,5‐a]pyridine‐8‐carboxylate	(13):	Recrys‐
tallized	from	dioxane.	Color:	Pale	brown.	Yield:	38%.	M.p.:	155	
C.	 FT‐IR	 (KBr,	 ,	 cm‐1):	 3275,	 3262	 (NH),	 3119	 (CH),	 2215	
(CN),	 1689	 (C=O),	 1669	 (C=O),	 1635	 (C=N);	 1584	 (C=C).	 1H	
NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	1.23	(t,	6H,	2CH3),	3.77	(s,	
6H,	 2OCH3,	 4.11	 (q,	 4H,	 2CH2)),	 4.61	 (s,	 2H,	 SCH2),	 8.74,	 8.78	
(brs,	 2H,	 2NH,	 D2O‐exchangeable),	 6.71‐6.79	 (m,	 4H,	 Ar‐H),	
7.22‐7.27	(m,	4H,	Ar‐H).		
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MS	(EI,	m/z	(%)):	752	(M+,	15).	13C	NMR	(75	MHz,	CDCl3,	δ,	
ppm):	 167.3,	 161.5	 (4C=O),	 153.7	 (2C‐2triazole),	 159.3	 (2C‐
ArOCH3‐p),	 152.1	 (2C‐7),	 146.8	 (2C‐8a),	 115.9	 (2CN),	 108.9	
(2C‐8),	128.1,	125.2,	115.4,	114.3,	109.2	(12C‐Ar),	61.9	(2CH2),	
55.8	 (2OCH3),	 19.7	 (‐SCH2S‐),	 14.1	 (2CH3).	 Anal.	 calcd.	 for	
C35H28N8O8S2:	 C,	 55.84;	 H,	 3.75;	 N,	 14.89.	 Found:	 C,	 55.79;	 H,	
3.81;	N,	14.86%.		
	
2.2.2.	Synthesis	of	3‐(3,3‐bis(methylthio)acryloyl)‐2H‐
chromen‐2‐one	(7)	
	
Prepared	according	to	procedure	[52],	to	a	solution	of	NaH	
(0.45	mol)	in	benzene	(150	mL),	a	solution	of	compound	6	(0.2	
mol),	CS2	(0.2	mol)	in	dry	DMF	(100	mL)	was	added	in	portions	
during	1	h.	The	reaction	mixture	was	kept	under	stirring	for	3	
h.	 followed	by	addition	of	methyl	 iodide	 (0.4	mol)	 in	portions	
with	 cooling.	 The	 reaction	 mixture	 was	 allowed	 to	 stand	 at	
room	 temperature	 for	 6	 h.	 and	 then	 refluxed	 for	 further	 4	 h.	
After	 cooling,	 it	 pour	 into	 ice	 water	 with	 stirring.	 The	
precipitate	 obtained	 was	 filtered	 off	 and	 washed	 was	 cold	
water	several	times	and	dried	(Scheme	2).	Recrystallized	from	
DMF/EtOH.	Color:	Buff	 crystals.	Yield:	63%.	M.p.:	92	C.	FT‐IR	
(KBr,	 ,	 cm‐1):	 3114	 (CH),	 1697	 (C=O).	 1H	 NMR	 (300	 MHz,	
DMSO‐d6,	 δ,	 ppm):	2.35	 (s,	 6H,	2CH3),	 6.21	 (s,	 1H,	C=H),	7.09‐
7.35	 (m,	 4H,	 Ar‐H),	 8.43	 (s,	 1H,	H‐4chromen).	MS	 (EI,	m/z	 (%)):	
291	 (M+,	 29).	 Anal.	 calcd.	 for	 C14H12O3S2:	 C,	 57.51;	 H,	 4.14.	
Found:	C,	57.49;	H,	4.04%.	
	
2.2.3.	Synthesis	of	3‐(6‐ethoxy‐2‐mercaptopyrimidin‐4‐yl)‐
2H‐chromen‐2‐one	(8)	
	
Prepared	according	 to	procedure	 [52],	 to	a	solution	of	 the	
sodium	 ethoxide	 ((0.04	mol)	 of	 Na	 in	 75	 (mL)	 of	 EtOH)	 was	
added	 compound	7	 (0.02	mol)	 and	 the	 reaction	mixture	 was	
refluxed	for	10‐12	h.	The	solvent	was	removed	under	reduced	
pressure	 and	 the	 residue	was	 treated	with	 glacial	 acetic	 acid	
(15	mL)	to	dissolve	the	sodium	salt	of	pyrimidine	and	refluxed	
for	 15	min.	 The	 reaction	mixture	was	 poured	 on	 crushed	 ice	
and	the	precipitate	was	filtered	off	and	washed	was	cold	water	
several	 times	and	dried	 (Scheme	2).	Recrystallized	 from	DMF.	
Color:	 Brownish‐yellow.	 Yield:	 51%.	 M.p.:	 215‐217	 C.	 FT‐IR	
(KBr,	,	cm‐1):	3145	(NH),	1165	(C=S),	3119	(CH),	1695	(C=O).	
1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	1.28	(t,	3H,	CH3),	4.29	(q,	
2H,	CH2),	6.81	(s,	1H,	H‐5),	7.11‐7.34	(m,	4H,	Ar‐H),	8.05	(s,	1H,	
H‐4chromen),	 8.65	 (brs,	 1H,	 SH,	D2O‐exchangeable).	MS	 (EI,	m/z	
(%)):	 300	 (M+,	 57).	 Anal.	 calcd.	 for	 C15H12N2O3S:	 C,	 59.99;	 H,	
4.03;	N,	9.33.	Found:	C,	59.94;	H,	4.01;	N,	9.36%.	
2.2.4.	Synthesis	of	ethyl	2‐((chloromethyl)thio)‐6‐cyano‐7‐
(4‐methoxphenyl)‐5‐oxo‐3,5‐dihydro‐[1,2,4]triazolo[1,5‐a]	
pyridine‐8‐carboxylate	(12)	
	
Prepared	 according	 to	 procedure,	 to	 a	 solution	 of	
compound	 1	 (20	 mmol)	 in	 THF	 50	 (mL)	 containing	 catalytic	
amount	of	NaH	was	added	CH2Cl2	(23	mmol)	and	the	reaction	
mixture	was	refluxed	for	6	h.	The	solvent	was	removed	under	
reduced	 pressure	 and	 the	 reaction	 mixture	 was	 poured	 on	
crushed	ice	containing	AcOH	and	the	precipitate	was	filtered	off	
and	washed	was	 cold	water	 several	 times	 and	 dried	 (Scheme	
3).	 Recrystallized	 from	 DMF.	 Color:	 Brown.	 Yield:	 43%.	 M.p.:	
225‐227	C.	FT‐IR	(KBr,	,	 cm‐1):	3362	 (NH),	3118	(CH),	2908	
(CH)	 2116	 (CN),	 1688	 (C=O),	 1661	 (C=O),	 1630	 (C=N);	 1581	
(C=C).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	1.16	(t,	3H,	CH3),	
3.74	(s,	3H,	OCH3),	4.08	(q,	2H,	CH2),	4.89	(s,	2H,	SCH2),	8.64	(s,	
1H,	 NH,	 D2O‐exchangeable),	 6.62‐7.89	 (m,	 4H,	 Ar‐H).	 MS	 (EI,	
m/z	 (%)):	 420	 (M++2,	 33),	 418	 (M+,	 59.6).	 	 Anal.	 calcd.	 for	
C18H15N4O4SCl:	 C,	 51.62;	H,	 3.61;	N,	 13.38.	 Found:	 C,	 51.58;	H,	
3.59;	N,	13.31%.	
	
2.2.5.	General	procedure	for	synthesis	of	compounds	4a,	4b,	
10	and	14	
	
A	 solution	 of	 p‐toluene‐sulfonyl	 chloride	 (20	 mmol)	 in	
pyridine	 (50	 mL)	 was	 added	 dropwise	 to	 a	 solution	 of	
compound	 3a	 and	 13	 (10	 mmol)	 or	 a	 solution	 of	 p‐toluene‐
sulfonyl	 chloride	 (10	 mmol)	 in	 pyridine	 (50	 mL)	 was	 added	
drop‐wise	to	a	solution	of	compound	3b	and	9	(10	mmol)	at	0	
C,	within	 6	 h.	 The	mixture	was	 stirred	 at	 room	 temperature	
and	 left	 overnight.	 It	 was	 then	 quenched	 with	 ice‐water	
containing	 HCl,	 and	 stirred	 for	 another	 1	 h.	 The	 precipitate	
obtained	was	filtered	off	and	washed	was	methanol,	cold	water	
several	 times,	 dried	 and	 recrystallized	 from	 the	 appropriate	
solvent	(Scheme	1‐3).	
Ethyl	 2‐((1‐tosyl‐1H‐benzo[d]imidazol‐2‐yl)methylthio)‐6‐
cyano‐3,5‐dihydro‐7‐(4‐methoxyphenyl)‐5‐oxo‐3‐tosyl‐[1,2,4]‐
triazolo[1,5‐a]pyridine‐8‐carboxylate	 (4a):	 Recrystallized	 from	
DMF/H2O.	 Color:	 Pale	 brown.	 Yield:	 46%.	M.p.:	 164	 C.	 FT‐IR	
(KBr,	,	cm‐1):	1372	(O=S=O),	3116	(CH),	2898	(CH),	2214	(CN),	
1676	 (C=O),	 1665	 (C=O),	 1630	 (C=N);	 1370	 (O=S=O),	 1580	
(C=C).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	1.21	(t,	3H,	CH3),	
2.36	(brs,	6H,	2CH3),	3.73	(s,	3H,	OCH3),	4.21	(q,	2H,	CH2),	5.11	
(s,	2H,	SCH2),	6.84‐7.92	(m,	16H,	Ar‐H).	MS	(EI,	m/z	(%)):	808	
(M+,	 37).	 	 Anal.	 calcd.	 for	 C39H32N6O8S3:	 C,	 57.91;	 H,	 3.99;	 N,	
10.39.	Found:	C,	57.87;	H,	3.96;	N,	10.37%.	
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Ethyl	 2‐((benzo[d]oxazol‐2‐ylmethyl)thio)‐6‐cyano‐7‐(4‐
methoxyphenyl)‐5‐oxo‐3‐tosyl‐3,5‐dihydrol‐[1,2,4]‐triazolo[1,5‐
a]pyridine‐8‐carboxylate	(4b):	Recrystallized	 from	DMF.	Color:	
Brownish‐yellow.	Yield:	39%.	M.p.:	197	C.	FT‐IR	(KBr,	,	cm‐1):	
3116	(CHarom.),	2891,	2850	(CH),	2216	(CN),	1681	(C=O),	1669	
(C=O),	1635	(C=N);	1583	(C=C).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	
ppm):	 1.19	 (t,	 3H,	 CH3),	 2.34	 (s,	 3H,	 CH3),	 3.74	 (s,	 3H,	 OCH3),	
4.19	(q,	2H,	CH2),	5.22	(s,	2H,	SCH2),	6.79‐7.85	(m,	12H,	Ar‐H).	
MS	(EI,	m/z	(%)):	655	(M+,	42).		Anal.	calcd.	for	C32H25N5O7S2:	C,	
58.62;	H,	3.84;	N,	10.68.	Found:	C,	58.58;	H,	3.82;	N,	10.67%.	
3(2‐((1‐Tosyl‐1H‐benzo[d]imidazol‐2‐yl)methylthio)‐6‐
ethoxypyrimidin‐4‐yl)‐2H‐chromen‐2‐one	 (10):	 Recrystallized	
from	dioxane/H2O.	Color:	Pale	yellow	crystals.	Yield:	49%.	M.p.:	
168	C.	FT‐IR	(KBr,	,	cm‐1):	3118	(CH),	2893	(CH),	1694	(C=O),	
1630	 (C=N),	 1180	 (O=S=O).	 1H	 NMR	 (300	 MHz,	 DMSO‐d6,	 δ,	
ppm):	1.29	(t,	3H,	CH3),	2.35	(s,	3H,	CH3),	3.89	(q,	2H,	CH2),	5.22	
(s,	2H,	SCH2),	6.83	(s,	1H,	H‐5),	7.11‐7.96	(m,	12H,	Ar‐H),	7.98	
(s,	1H,	H‐4chromen).	MS	(EI,	m/z	(%)):	584	(M+,	19).	 	Anal.	calcd.	
for	C30H24N4O5S2:	C,	61.63;	H,	4.14;	N,	9.58.	Found:	C,	61.59;	H,	
4.11;	N,	9.55%.	
Ethyl	 2‐(((8‐(ethoxycarbonyl)‐6‐cyano‐3,5‐dihydro‐7‐(4‐
methoxyphenyl)‐5‐oxo‐3‐tosyl‐[1,2,4]‐triazolo[1,5‐a]pyridine‐2‐
ylthio)methyl)sulfanyl)‐6‐cyano‐3,5‐dihydro‐7‐(4‐methoxy	
phenyl)‐5‐oxo‐3‐tosyl‐[1,2,4]triazolo[1,5‐a]pyridine‐8‐carboxy	
late	 (14):	 Recrystallized	 from	 DMF/H2O.	 Color:	 Brown.	 Yield:	
65%.	M.p.:	 149‐151	 C.	 FT‐IR	 (KBr,	,	 cm‐1):	 3119	 (CH),	 2855	
(CH),	 2218	 (CN),	 1683	 (C=O),	 1663	 (C=O),	 1630	 (C=N);	 1377	
(O=S=O).	 1H	 NMR	 (300	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 1.24	 (t,	 6H,	
2CH3),	 2.36	 (s,	 6H,	 2CH3),	 4.18	 (q,	 4H,	 2CH2),	 3.75	 (s,	 6H,	
2OCH3),	 4.68	 (s,	 2H,	 SCH2),	 7.15‐7.89	 (m,	 16H,	 Ar‐H).	 Anal.	
calcd.	 for	 C49H40N8O12S4:	 C,	 55.46;	H,	 3.80;	N,	 10.56.	 Found:	 C,	
55.40;	H,	3.79;	N,	10.53%.		
	
2.2.6.	General	procedure	for	synthesis	of	compound	5a,	5b,	
and	11	
	
Prepared	 according	 to	 procedure	 [53],	 to	 a	 solution	 of	
compound	 4a,	 4b,	 10	 and	 14	 (20	mmol)	 in	 CH2Cl2	 (50	 mL),	
H2O2	(30%	w:v,	0.3	mL,	20	mmol	in	case	of	compound	4a,	4b,	9	
and	(0.6	mL),	(40	mmol)	in	case	of	compound	14)	in	AcOH	(10	
mL)	was	added	dropwise.	The	reaction	mixture	was	heated	at	
80	C	under	stirring	for	3‐6	h.	The	solvent	was	then	evaporated	
under	reduced	pressure.	The	residue	was	poured	 in	methanol	
ice	 cold	 water.	 The	 precipitate	 obtained	 was	 filtered	 off	 and	
washed	with	cold	water	several	times,	dried	and	recrystallized	
from	the	appropriate	solvent	(Scheme	1	and	2).	
2‐((1‐Tosyl‐1H‐benzo[d]imidazol‐2‐yl)methylsulfinyl)‐6‐
cyano‐3,5‐dihydro‐7‐(4‐methoxyphenyl)‐5‐oxo‐3‐tosyl‐[1,2,4]	
triazolo[1,5‐a]pyridine‐8‐yl	propionate	(5a):	Recrystallized	from	
DMF.	Color:	Brown.	Yield:	33%.	M.p.:	247‐249	C.	FT‐IR	(KBr,	,	
cm‐1):	 3114	 (CH),	 2890	 (CH),	 2209	 (CN),	 1676	 (C=O),	 1661	
(C=O),	1633	(C=N);	1583	(C=C).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	
ppm):	1.26	(t,	3H,	CH3),	2.34‐2.36	(brs,	6H,	2CH3),	3.75	(s,	3H,	
OCH3),	4.23	(q,	2H,	CH2),	5.40	(s,	2H,	SCH2),	6.72‐7.81	(m,	16H,	
Ar‐H).	 MS	 (EI,	 m/z	 (%)):	 824	 (M+,	 8).	 Anal.	 calcd.	 for	
C39H32N6O9S3:	 C,	 56.78;	 H,	 3.91;	 N,	 10.19.	 Found:	 C,	 56.71;	 H,	
3.89;	N,	10.17%.		
2‐((Benzo[d]oxazol‐2‐yl)methylsulfinyl)‐6‐cyano‐3,5‐dihyd	
ro‐7‐(4‐methoxyphenyl)‐5‐oxo‐3‐tosyl‐[1,2,4]‐triazolo[1,5‐a]	
pyridine‐8‐yl	propionate	 (5b):	Recrystallized	 from	DMF.	 Color:	
Pale	brown.	Yield:	43%.	M.p.:	243‐244	C.	FT‐IR	(KBr,	,	cm‐1):	
3119	 (CH),	 2895,	 2857	 (CH)	 2213	 (CN),	 1679	 (C=O),	 1668	
(C=O),	1631	(C=N);	1585	(C=C).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	
ppm):	1.24	(t,	3H,	CH3),	2.35	(s,	3H,	2CH3),	3.73	(s,	3H,	OCH3),	
4.21	(q,	2H,	CH2),	5.42	(s,	2H,	SCH2),	6.72‐7.81	(m,	12H,	Ar‐H).	
MS	(EI,	m/z	(%)):	671	(M+,	16).	Anal.	calcd.	for	C32H25N5O8S2:	C,	
57.22;	H,	3.75;	N,	10.43.	Found:	C,	57.16;	H,	3.74;	N,	10.41%.	
3‐(2‐((1‐Tosyl‐1H‐benzo[d]imidazol‐2‐yl)methylsulfinyl)‐6‐
ethoxypyrimidin‐4‐yl)‐2H‐chromen‐2‐one	 (11):	 Recrystallized	
from	DMF/EtOH.	Color:	Dark	brown.	Yield:	38%.	M.p.:	205‐206	
C.	 FT‐IR	 (KBr,	 ,	 cm‐1):	 3145	 (CH),	 2894	 (CH),	 1694	 (C=O),	
1634	(C=N),	1583	(C=C).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	
1.3	(t,	3H,	CH3),	2.35	(s,	3H,	CH3),	3.98	(q,	2H,	CH2),	5.55	(s,	2H,	
SCH2),	6.82	(s,	1H,	H‐5),	7.13‐7.93	(m,	12H,	Ar‐H),	8.03	(s,	1H,	
H‐4chromen).	 MS	 (EI,	 m/z	 (%)):	 600	 (M+,	 11).	 Anal.	 calcd.	 for	
C30H24N4O6S2:	C,	59.99;	H,	4.03;	N,	9.33.	Found:	C,	59.92;	H,	4.0;	
N,	9.29%.	
	
2.3.	Biological	activity	
	
2.3.1.	Tested	organisms	
	
Eight	organisms	are	used	as	 test	organisms	 comprising	of	
five	 bacteria	 (Staphylococcus	 aureus,	 Bacillus	 sp.,	 Salmonella	
typhi,	Escherichia	coli	[54,55],	and	Nisseria	lactmica	[56])	were	
obtained	 from	Microbiology	 Laboratory	 of	 Faculty	 of	 Science,	
Qena	 and	 three	 fungi	 (Alternaria	 alternata	 strain	 HM01	 [57],	
Aspergillus	 terreus	 strain	 HM13	 [58],	 Fusarium	 nivale	 strain	
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HM25)	were	obtained	from	Mycology	Laboratory	of	Faculty	of	
Science,	 Aswan	 .The	 cultures	 of	 bacteria	 and	 fungi	were	 sub‐
cultured	 on	 Muller‐Hinton	 agar	 and	 C'zapek's‐agar	 slants	
respectively	and	stored	at	4	C	until	required	for	study.	
	
2.3.2.	Antibacterial	test	using	paper	disc	technique	
	
The	 tested	 compounds	 (1	mg/disc)	 on	 sterile	 filter	 paper	
discs	(0.3	mm	diameter)	and	dried	at	40	C	for	30	minutes.	The	
prepared	Muller‐Hinton	agar	plates	were	on	cultured	with	each	
of	 test	 bacteria	 107	 CFU/mL,	 and	 the	 filter	 paper	 discs	 were	
placed	on	each	plate.	The	plates	were	incubated	at	37	C	for	24	
h.	The	zones	of	inhibition	were	measured	and	recorded.	
	
2.3.3.	Antifungal	test	using	fungal	growth	rate	technique	
	
This	activity	was	carried	out	using	C’zapekes	agar	medium	
in	 petri	 dishes	 and	 mixed	 with	 each	 compound	 by	 a	 final	
concentration	(1	mg/plate)	and	then	inoculated	in	central	zone	
with	a	fresh	culture	fungal	disc	of	3	mm	in	diameter.	All	plates	
were	 incubated	 at	 28	 C.	 The	 diameters	 of	 cultures	 were	
measured	in	control	dishes	and	in	the	treated	plates	containing	
culture	 medium	 supplemented	 with	 variable	 compounds	 and	
the	average	growth	rates	was	measured.	
	
3.	Results	and	discussion	
	
3.1.	Synthesis	
	
1,2,4‐Triazolo[1,5‐a]pyridine	 derivative	 (3a)	were	 synthe‐
sized	by	stirring	of	ethyl	6‐cyano‐7‐(4‐methoxyphenyl)‐5‐oxo‐
2‐thioxo‐1,2,3,5‐tetrahydro[1,2,4]triazolo[1,5‐a]pyridine‐8‐
carboxylate	 (1)	 with	 2‐(chloromethyl)benzimidazole	 (2a)	 in	
sodium	 methoxide.	 The	 structure	 of	 the	 product	 3a	 was	
assigned	as	 ethyl	 2‐((1H‐benzo[d]imidazol‐2‐yl)methylthio)‐6‐
cyano‐3,5‐dihydro‐7‐(4‐methoxyphenyl)‐5‐oxo‐[1,2,4]triazolo‐
[1,5‐a]pyridine‐8‐carboxylate	 based	 on	 the	 elemental	 analysis	
and	spectral	data	which	in	agreement	with	this	structure.	Its	IR	
spectrum	 indicate	 the	 absence	 of	 a	 free	 –SH	 absorption	 band	
and	 the	 appearance	 of	 absorption	 bands	 at	 3375,	 3268	 cm‐1	
assignable	 to	 2NH,	 3115	 cm‐1	 to	 CH,	 2212	 cm‐1	 to	 CN,	 1685,	
1664	 cm‐1	 to	CO,	 and	1586	 cm‐1	 to	C=C	 functions.	 Its	 1H	NMR	
spectrum	 revealed	 the	 presence	 of	 three	 singlet	 signals	 at	 	
11.43	ppm,		8.64	ppm,		4.64	ppm	assignable	to	the	NHimidazole,	
NHtriazole,	 and	 SCH2,	 respectively.	 The	 mass	 spectrum	 of	
compound	 3a	 showed	 the	 molecular	 ion	 at	 m/z	 500	 (M+).	
Furthermore,	 the	 13C	 NMR	 spectrum	 also	 revealed	 signal	 at	
33.4	ppm	due	to	SCH2	(Scheme	1).	
Similarly,	2‐(chloromethyl)benzooxazole	(2b)	reacted	with	
compound	1	under	the	same	conditions	to	yield	compound	3b.	
The	 structure	 of	 the	 product	 3b	 was	 assigned	 as	 ethyl	 2‐
((benzo[d]oxazol‐2‐yl)methylthio)‐6‐cyano‐3,5‐dihydro‐7‐(4‐
methoxyphenyl)‐5‐oxo‐[1,2,4]triazolo[1,5‐a]pyridine‐8‐
carboxylate	based	on	 the	elemental	analysis	and	spectral	data	
which	 in	 agreement	 with	 this	 structure	 (see	 Experimental	
section).	
Reaction	 of	 compound	3a	 with	 tosyl	 chloride	 in	 pyridine	
gave	the	corresponding	ethyl	2‐((1‐tosyl‐1H‐benzo[d]imidazol‐
2‐yl)methylthio)‐6‐cyano‐3,5‐dihydro‐7‐(4‐methoxyphenyl)‐5‐
oxo‐3‐tosyl‐[1,2,4]‐triazolo[1,5‐a]pyridine‐8‐carboxylate,	 4a.	
Its	 IR	spectrum	indicate	 the	absence	of	a	 free	2NH	absorption	
bands	 and	 the	 appearance	 of	 absorption	 bands	 at	 1372	 cm‐1	
assignable	to	SO2,	2214	cm‐1	to	CN,	and	1676,	1655	cm‐1	to	CO	
functions.	Its	1H	NMR	spectrum	revealed	the	presence	of	singlet	
signal	at		5.11	ppm	assignable	to	SCH2	(Scheme	1).	
Similarly,	 reaction	 of	 compound	3b	with	 tosyl	 chloride	 in	
pyridine	 gave	 the	 corresponding	 4b.	 The	 structure	 of	 the	
product	 4b	 was	 assigned	 as	 ethyl	 2‐((benzo[d]oxazol‐2‐
ylmethyl)thio)‐6‐cyano‐7‐(4‐methoxyphenyl)‐5‐oxo‐3‐tosyl‐
3,5‐dihydrol‐[1,2,4]‐triazolo[1,5‐a]pyri‐dine‐8‐carboxylate	
based	 on	 the	 elemental	 analysis	 and	 spectral	 data	 which	 in	
agreement	with	this	structure	(see	Experimental	section).	
2‐((1‐Tosyl‐1H‐benzo[d]imidazol‐2‐yl)methylsulfinyl)‐6‐
cyano‐3,5‐dihydro‐7‐(4‐methoxyphenyl)‐5‐oxo‐3‐tosyl‐[1,2,4]‐
triazolo[1,5‐a]pyridine‐8‐yl	 propionate	 (5a)	 was	 synthesized	
by	 refluxing	 with	 stirring	 a	 solution	 of	 compound	 4a	 in	
dichloromethane	 and	 hydrogen	 peroxide	 in	 acetic	 acid.	 Its	 IR	
spectrum	showed	absorption	bands	at	2209	cm‐1	assignable	to	
CN	and	1676,	1661	cm‐1	to	CO	functions.	Its	1H	NMR	spectrum	
revealed	the	presence	of	singlet	signal	at		5.4	ppm	assignable	
to	 ‐SCH2.	 The	 mass	 spectrum	 of	 compound	 5a	 showed	 the	
molecular	ion	at	m/z	824	(M+)	(Scheme	1).	
Similarly,	 refluxing	 with	 stirring	 compound	 4b	 in	
dichloromethane	and	hydrogen	peroxide	in	acetic	acid	yield	the	
corresponding	 compound	5b.	 The	 structure	 of	 compound	 5b	
was	 assigned	 as	 2‐((benzo[d]oxazol‐2‐yl)methylsulfinyl)‐6‐
cyano‐3,5‐dihydro‐7‐(4‐methoxyphenyl)‐5‐oxo‐3‐tosyl‐[1,2,4]‐
triazolo[1,5‐a]pyridine‐8‐yl	propionate	based	on	the	elemental	
analysis	 and	 spectral	 data	 which	 in	 agreement	 with	 this	
structure	(see	Experimental	section).	
In	continuation	of	our	 interest	with	 the	 synthesis	of	 fused	
hetero	 compounds	 [36],	 reaction	 of	 3‐acetyl‐2H‐chromen‐3‐
one	 (6)	 with	 CS2	 in	 the	 presence	 of	 NaH	 followed	 by	
methylation	 with	 CH3I	 to	 afford	 3‐(3,3‐bis(methylthio)	
acryloyl)‐2H‐chromen‐2‐one,	7.	 The	 1H	 NMR	 spectrum	 of	 the	
latter	exhibited	two	characteristic	singlet	signals	at		8.43	and	
6.21	ppm	for	coumarine	H‐4	and	=CH	proton,	respectively.	The	
mass	spectrum	of	compound	7	showed	the	molecular	ion	peak	
at	 m/z	 293	 (M++1)	 corresponding	 to	 the	 molecular	 formula	
(C14H12O3S2).	Reaction	of	compound	7	with	thiourea	in	sodium	
ethoxide	 afforded	 the	 pyrimidine	 derivative,	 8.	 The	 1H	 NMR	
spectrum	 exhibited	 a	 broad	 signal	 at	 at	 	 8.65	 ppm	 for	 SH	
proton	of	pyrimidine	and	singlet	signal	for	pyrimidine	H‐5	at		
6.81	 ppm.	 The	 mass	 spectrum	 of	 compound	 8	 showed	 the	
molecular	ion	peak	at	m/z	300	corresponding	to	the	molecular	
formula	(C15H12N2O3S).	
Chromen‐2‐one	derivative	9	was	synthesized	by	stirring	of	
3‐(6‐ethoxy‐2‐marcaptopyrimidin‐4‐yl)‐2H‐chromen‐2‐one	 (8)	
with	 compound	 2a	 in	 sodium	 methoxide	 (Scheme	 2).	 The	
structure	 of	 the	 product	 9	 was	 assigned	 as	 3‐(2‐((1H‐benzo	
[d]imidazol‐2‐yl)methylthio)‐6‐ethoxypyrimidin‐4‐yl)‐2H‐chro	
men‐2‐one	 based	 on	 the	 elemental	 analysis	 and	 spectral	 data	
which	 in	 agreement	 with	 this	 structure.	 Its	 IR	 spectrum	
indicate	 the	 absence	 of	 a	 free	 –SH	 absorption	 band	 and	 the	
appearance	of	absorption	bands	at	3279	cm‐1	assignable	to	NH,	
3119	 cm‐1	 to	 CH	 and	 1691	 cm‐1	 to	 COchromen	 functions.	 Its	 1H	
NMR	spectrum	revealed	the	presence	of	two	singlet	signals	at		
11.13	 and	 4.39	 ppm	 assignable	 to	 the	 NH	 and	 SCH2,	
respectively.	 The	 mass	 spectrum	 of	 compound	 9	 showed	 the	
molecular	ion	at	m/z	430	(M+).	
Reaction	 of	 compound	 9	 with	 tosyl	 chloride	 in	 pyridine	
gave	 the	 corresponding	 3(2‐((1‐tosyl‐1H‐benzo[d]imidazol‐2‐
yl)methylthio)‐6‐ethoxypyrimidin‐4‐yl)‐2H‐chromen‐2‐one,	
10.	The	structure	of	 the	compound	10	was	assigned	based	on	
the	 elemental	 analysis	 and	 spectral	 data.	 Its	 IR	 spectrum	
indicate	 the	 absence	 of	 a	 free	 NH	 absorption	 band	 of	 the	
benzimidazole	and	the	appearance	of	absorption	bands	at	1180	
cm‐1	 assignable	 to	 SO2	 and	 1694	 cm‐1	 to	 CO	 functions.	 Its	 1H	
NMR	spectrum	revealed	the	presence	of	two	singlet	signals	at		
2.35	ppm,	and	5.22	ppm	assignable	 to	 the	methyl	of	 tosyl	and	
SCH2	 protons,	 whereas	 the	 aromatic	 protons	 appeared	 as	
multiplets	 and	 doublet	 signals	 at	 	 7.11‐7.96	 ppm.	 The	mass	
spectrum	 of	 compound	10	 showed	 the	molecular	 ion	 at	m/z	
584	(M+)	(Scheme	2).	
3‐(2‐((1‐Tosyl‐1H‐benzo[d]imidazol‐2‐yl)methylsulfinyl)‐
6‐ethoxypyrimidin‐4‐yl)‐2H‐chromen‐2‐one	 (11)	 was	 synthe‐
sized	by	 refluxing	with	 stirring	 a	 solution	of	 compound	10	 in	
dichloromethane	and	hydrogen	peroxide	 in	acetic	acid.	The	IR	
spectrum	 of	 compound	11	 showed	 absorption	 bands	 at	 3145	
cm‐1	assignable	to	CH	and	1694	cm‐1	to	CO	function.		
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Table	1.	The	antibacterial	activity	of	compounds	(1	mg/disc)	*.	
Compound	no	 Staphylococcus	aureus		
Gram	(+) 
Bacillus	sp.		
Gram	(+)
Escherichia	coli	
Gram	(+)
Neisseria	Lactamica		
Gram	(+)
Salmonella	Typhi		
Gram	(‐)	
3a	 +	 ‐	 ‐ ‐ ‐	
3b	 ‐	 ‐	 +	 ‐	 ‐	
4a	 +	 ‐	 +	 ‐	 ‐	
9	 +	 +	 +	 +	 +	
13	 +	 ‐	 +	 +	 +	
5a	 ‐	 ‐	 ‐ ‐ ‐	
5b	 ‐	 ‐	 + ‐ ‐	
10	 +	 +	 + + +	
14	 +	 +	 + + +	
4b	 ‐	 ‐	 + ‐ ‐	
11	 +	 ‐	 ‐ + +	
*	“+”	=	active;	“‐“	=	non‐active.	
	
	
Table	2.	Effect	of	the	compounds	(1	mg/plate)	on	fungal	growth	rate.	
Compounds	 Altermaria	altermata	 Aspergillus	terreus	 Fusarium	nivale	
3a	 2.30	 1.3 3.7	
3b	 3.05	 1.2	 3.0	
4a	 2.20	 1.5 3.1	
9	 2.60	 1.1	 2.9	
13	 2.60	 0.9	 3.9	
5a	 3.40	 1.3	 3.8	
5b	 2.50	 1.2 4.2	
10	 2.25	 1.2 3.1	
14	 2.60	 1.1 3.7	
4b	 2.60	 1.3 4.0	
11	 2.60	 1.1 3.1	
	
	
Its	1H	NMR	spectrum	revealed	the	presence	of	singlet	signal	
at		2.35	and	5.55	ppm	assignable	to	methyl	of	tosyl	and	‐CH2S,	
whereas	the	aromatic	protons	appeared	as	multiplets	signals	at	
	7.13‐7.93	ppm.	The	mass	spectrum	of	compound	11	showed	
the	molecular	ion	at	m/z	600	(M+)	(Scheme	2).	
1,2,4‐Triazolo[1,5‐a]pyridine‐8‐carboxylate	 derivative	 12	
was	 synthesized	 by	 refluxing	 of	 compound	 1	 with	 dichloro	
methane	 in	 a	 solution	of	THF	 containing	 sodium	hydride	 as	 a	
basic	catalyst	(Scheme	3).	The	structure	of	the	product	12	was	
assigned	 as	 ethyl	 2‐((chloromethyl)thio)‐6‐cyano‐7‐(4‐methox	
phenyl)‐5‐oxo‐3,5‐dihydro‐[1,2,4]triazolo[1,5‐a]pyridine‐8‐
carboxylate	based	on	 the	elemental	analysis	and	spectral	data	
which	 in	 agreement	 with	 this	 structure.	 Its	 IR	 spectrum	
indicate	 the	 absence	 of	 a	 free	 –SH	 absorption	 band	 and	 the	
appearance	of	absorption	bands	at	3362	cm‐1	assignable	to	NH,	
3118	cm‐1	 to	CH,	2116	cm‐1	 to	CN,	and	1688,	1661	cm‐1	 to	CO	
functions.	Its	1H	NMR	spectrum	revealed	the	presence	of	three	
singlet	 signals	 at	 	 8.64	 and	 4.89	 ppm,	 assignable	 to	 the	
NHtriazole,	 and	 SCH2,	 respectively.	 The	 mass	 spectrum	 of	
compound	12	showed	the	molecular	ion	at	m/z	420	(M+2,	33),	
418	(M+,	59.6).	
Reaction	 of	 compound	 12	 with	 compound	 1	 in	 sodium	
methoxide	with	stirring	afforded	1,2,4‐triazolo[1,5‐a]pyridine‐
8‐carboxylate	 derivative	 13	 (Scheme	 3).	 The	 structure	 of	 the	
product	 13	 was	 assigned	 as	 ethyl	 2‐(((8‐(ethoxycarbonyl)‐6‐
cyano‐3,5‐dihydro‐7‐(4‐methoxyphenyl)‐5‐oxo‐[1,2,4]triazolo	
[1,5‐a]pyridine‐2‐ylthio)methyl)sulfanyl)‐6‐cyano‐3,5‐dihydro‐
7‐(4‐methoxyphenyl)‐5‐oxo‐[1,2,4]triazolo[1,5‐a]pyridine‐8‐
carboxylate	based	on	 the	elemental	analysis	and	spectral	data	
which	 in	 agreement	 with	 this	 structure.	 Its	 IR	 spectrum	
indicate	 the	 appearance	 of	 absorption	 bands	 at	 3275	 cm‐1	
assignable	to	NH,	3119	cm‐1	to	CH,	2215	cm‐1	to	CN,	and	1689,	
1669	 cm‐1	 to	CO	 functions.	 Its	 1H	NMR	spectrum	revealed	 the	
presence	of	a	broad	singlet	signal	at		8.78	ppm	assignable	 to	
NHtriazole	and	singlet	signal	at		4.61	ppm	to	‐SCH2S‐.	
Reaction	 of	 compound	13	 with	 tosyl	 chloride	 in	 pyridine	
gave	the	corresponding	ethyl	2‐(((8‐(ethoxycarbonyl)‐6‐cyano‐
3,5‐dihydro‐7‐(4‐methoxyphenyl)‐5‐oxo‐3‐tosyl‐[1,2,4]triazolo	
[1,5‐a]pyridine‐2‐ylthio)methyl)sulfanyl)‐6‐cyano‐3,5‐dihydro‐
7‐(4‐methoxyphenyl)‐5‐oxo‐3‐tosyl‐[1,2,4]triazolo[1,5‐a]pyridi	
ne‐8‐carboxylate,	14.	Its	IR	spectrum	indicate	the	absence	of	a	
free	 NH	 absorption	 bands	 and	 the	 appearance	 of	 absorption	
bands	 at	 1377	 cm‐1	 assignable	 to	 SO2,	 2218	 cm‐1	 to	 CN,	 and	
1683,	 1663	 cm‐1	 to	 CO.	 Its	 1H	 NMR	 spectrum	 revealed	 the	
presence	 of	 singlet	 signals	 at	 	 2.36	 ppm	 assignable	 to	 the	
methyl	protons	of	tosyl,	and		4.68	ppm	to	‐SCH2S‐	whereas	the	
aromatic	protons	appeared	as	multiplets	signals	at		7.15‐7.89	
ppm	(Scheme	3).	
	
3.2.	Antimicrobial	studies	
	
Only	 1	 mg	 of	 each	 compound	 was	 used	 to	 check	 its	
biological	 activity	 against	 bacteria	 (Table	 1)	 and	 fungi	 (Table	
2).	 The	 studied	 compounds	 showed	 biological	 activity	 with	
most	of	the	tested	bacteria	and	fungi.	Compounds	9,	10	and	14	
inhibited	 the	 growth	 of	 all	 testes	 bacteria	 while	 5a	 had	 no	
activity	 to	 any	 studied	 bacterial	 species.	 The	 remaining	
compounds	 activity	 recorded	 less	 toxicity	 to	 the	 tested	
bacterial	cell.	These	compounds	almost	inhibited	all	the	studied	
fungi	but	Aspergillus	terreus	was	slightly	resistance.	
Compounds	9,	10,	and	14	showed	inhibition	zones	with	all	
studied	 bacteria	 while	 compound	 13	 inhibit	 four	 bacterial	
species	(S.	aureus,	S.	typhi,	E.	coli	and	N.	lactamica).	However	11	
could	inhibit	S.	aureus,	S.	typhi,	and	N.	lactamica).	
The	 compound	 4a	 showed	 less	 activity	 against	 studied	
bacteria	which	could	inhibit	only	two	species	(S.	aureus	and	E.	
coli).	 Compounds	 3a,	 3b,	 5b	 and	 4b	 recorded	 the	 lowest	
inhibition	activity	where	the	first	one	inhibits	S.	aureus	and	the	
last	three	compounds	inhibit	only	E.	coli.	No	biological	activity	
was	recorded	with	compound	5a.	
The	toxicity	of	most	compounds	on	fungal	cells	was	slightly	
different	 from	 bacterial	 cells.	 Therefore,	 Alternaria	 alternata	
growth	 rate	 in	 control	 culture	 was	 (4.15	 cm).	 This	 growth	
decreased	to	almost	half	with	compound	4a,	10	and	3a	 (2.20,	
2.25	 and	 2.3	 cm),	 respectively. The	 toxicity	 effect	 slightly	
decrease	with	compounds	5b	 (2.5	 cm)	and	9,	13,	14,	4b,	 and	
11	 (2.6	 cm)	while	 with	 compounds	3b	 and	5a	 was	 3.05	 and	
3.40	cm,	respectively	(Table	2).	
In	case	of	Aspergillus	terreus	(Table	2)	its	growth	in	control	
culture	was	1.5	cm	which	similar	to	the	growth	with	compound	
4a	 (not	 toxic	 compound),	 whereas,	 slightly	 inhibition	 of	 the	
fungal	 growth	 was	 recorded	 with	 compound	 3a,	 5a,	 4b	 (1.3	
cm),	3b,	5b,	 and	10	 (1.2	 cm). This	 toxicity	 slightly	 increased	
with	compound	9,	14,	11	(1.1	cm),	and	13	(0.9	cm).	
Fusarium	 nivale	 was	 also	 sensitive	 to	 all	 compounds.	
Whereas	control	growth	rate	was	5	cm.	Compounds	9	and	3b	
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could	 inhibited	the	growth	 to	2.9	cm	and	3.0	cm,	respectively,	
while	compound	4a,	10	and	11	reduced	the	growth	rate	to	3.1	
cm.	The	 remaining	 compounds’	 toxicity	 on	 this	 fungal	 species	
decreased	 to	3.7	 cm	with	 compounds	3a	 and	14,	 3.8	 cm	with	
5a,	3.9	cm	with	13,	4.0	cm	with	4b,	and	4.2	cm	with	5b.	
	
4.	Conclusions		
	
In	the	present	work,	several	new	substituted	sulfonamides	
and	 sulfinyl	 compound	 derivatives	 were	 obtained	 by	 the	
reaction	 of	 2‐thioxo‐1,2,4‐triazolo[1,5‐a]pyridine	 and	 pyrimi	
dinethiol	 derivatives	 with	 (2‐chloromethyl)benzimidazole	
and/or	 (2‐chloromethyl)benzooxazole.	 A	 little	 amount	 (1	mg)	
of	compounds	9,	10	and	14	was	enough	to	inhibit	the	growth	of	
all	 testes	 bacteria	while	 compound	5a	 had	 no	 activity	 to	 any	
studied	 bacterial	 species.	 The	 remaining	 compounds	 activity	
recorded	 less	 toxicity	 to	 the	 tested	 bacterial	 cell.	 The	 tested	
compounds	 almost	 inhibited	 all	 the	 studied	 fungi	 but	
Aspergillus	terreus	was	slightly	resistance.	
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